FIGURE 1. Genome-Wide Meta-Analytic Results for Percentage Improvement and Remission After 12 Weeks of Antidepressant Treatment in Entire Analyzed Samples From Three Studies^a.

^a Data are from the Genome-Based Therapeutic Drugs for Depression (GENDEP) project, the Munich Antidepressant Response Signature (MARS) project, and the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Remission was measured using the Hamilton Depression Rating Scale. The y-axis plots indicate p values for associations on the negative logarithmic scale (–log₁₀[p values]). Gene symbols indicate the gene on which the associated single-nucleotide polymorphism (SNP) (p≤5×10⁻⁶) is located, or, if the gene symbol is in parentheses, the nearest gene up to 100 kb away from the associated SNP. An imputed SNP located in an intronic region of the myosin X (MYO10) gene at 5p15.1 achieved a genome-wide effect, which could not be validated in confirmatory follow-up genotyping.